Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Sangamo Biosciences ( (SGMO) ) is now available.
On February 3, 2026, Sangamo Therapeutics entered into an underwriting agreement with Cantor Fitzgerald and Wells Fargo Securities for an underwritten public offering of 35.19 million shares of common stock and pre-funded warrants for 17.79 million shares, each bundled with accompanying purchase warrants, for expected gross proceeds of about $25 million before fees. The securities, issued under an effective shelf registration, feature low exercise prices and structured ownership caps, with the offering anticipated to close on February 4, 2026, and Warrants becoming exercisable either immediately or six months after issuance for terms extending up to five and a half years. In a parallel move on February 3, 2026, Sangamo amended previously issued warrants from March 26, 2024, held by the same investor, cutting their exercise price from $1.00 to $0.4719 and extending their term to five and a half years from the offering’s close, a step that improves the likelihood of warrant exercise and further potential capital inflows while increasing prospective dilution for existing shareholders.
The most recent analyst rating on (SGMO) stock is a Hold with a $0.55 price target. To see the full list of analyst forecasts on Sangamo Biosciences stock, see the SGMO Stock Forecast page.
Spark’s Take on SGMO Stock
According to Spark, TipRanks’ AI Analyst, SGMO is a Neutral.
The score is held back primarily by weak financial performance (sharp revenue decline, ongoing losses and cash burn, and a weakened balance sheet). Offsetting this, the latest earnings call was favorable on clinical/regulatory progress for Fabry and runway extension, while technicals show above-average momentum but with overbought risk; valuation remains constrained by negative earnings and no dividend data.
To see Spark’s full report on SGMO stock, click here.
More about Sangamo Biosciences
Sangamo Therapeutics is a biotechnology company focused on developing genomic medicine, including gene-based therapies that leverage its proprietary platform technologies. The company operates in the biopharmaceutical sector, targeting serious diseases where gene regulation or gene editing could offer differentiated treatment options, and accesses capital markets to fund its research and development programs.
Average Trading Volume: 7,043,525
Technical Sentiment Signal: Sell
Current Market Cap: $191.1M
Find detailed analytics on SGMO stock on TipRanks’ Stock Analysis page.